Business Description
OrbusNeich Medical Group Holdings Ltd
ISIN : KYG6773B1005
Compare
Compare
Traded in other countries / regions
06929.Hong KongQ8T.Germany IPO Date
2023-05-16Description
OrbusNeich is a China-based global medical device maker of endovascular interventional instruments with global reach. It launched its first research base in 2001 and was listed on the Hong Kong Exchange in 2022. As of 2023, OrbusNeich's largest revenue segment by geography is Japan with 24.7% of total revenue followed by Europe, the Middle East, and Africa, with 23.6% of total revenue. The Asia-Pacific region and the United States make up the balance. Its largest product segment is coronary interventional medical devices, such as scoring balloons, non-compliant balloons, or stents, together representing 82.7% of its total revenue.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 30.21 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 6.36 | |||||
| Beneish M-Score | -1.73 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 20.3 | |||||
| 3-Year EBITDA Growth Rate | 62 | |||||
| 3-Year EPS without NRI Growth Rate | 91.6 | |||||
| 3-Year FCF Growth Rate | 20.7 | |||||
| 3-Year Book Growth Rate | 119.9 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 10.49 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.9 | |||||
| 9-Day RSI | 46.97 | |||||
| 14-Day RSI | 47.28 | |||||
| 6-1 Month Momentum % | 10.89 | |||||
| 12-1 Month Momentum % | -55.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.68 | |||||
| Quick Ratio | 8.32 | |||||
| Cash Ratio | 6.87 | |||||
| Days Inventory | 272.53 | |||||
| Days Sales Outstanding | 83.25 | |||||
| Days Payable | 34.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 3.83 | |||||
| Forward Dividend Yield % | 3.83 | |||||
| 5-Year Yield-on-Cost % | 3.93 | |||||
| Shareholder Yield % | 1.97 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 69.22 | |||||
| Operating Margin % | 25.61 | |||||
| Net Margin % | 29.29 | |||||
| FCF Margin % | 10.11 | |||||
| ROE % | 13.07 | |||||
| ROA % | 11.86 | |||||
| ROIC % | 30.26 | |||||
| 3-Year ROIIC % | 49.95 | |||||
| ROC (Joel Greenblatt) % | 78.4 | |||||
| ROCE % | 14.2 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 8.71 | |||||
| Forward PE Ratio | 6.76 | |||||
| PE Ratio without NRI | 8.64 | |||||
| Price-to-Owner-Earnings | 12.01 | |||||
| PS Ratio | 2.2 | |||||
| PB Ratio | 0.9 | |||||
| Price-to-Tangible-Book | 0.98 | |||||
| Price-to-Free-Cash-Flow | 21.71 | |||||
| Price-to-Operating-Cash-Flow | 14.68 | |||||
| EV-to-EBIT | 1.95 | |||||
| EV-to-Forward-EBIT | 3.24 | |||||
| EV-to-EBITDA | 1.8 | |||||
| EV-to-Forward-EBITDA | 2.81 | |||||
| EV-to-Revenue | 0.63 | |||||
| EV-to-Forward-Revenue | 0.51 | |||||
| EV-to-FCF | 6.24 | |||||
| Price-to-Net-Current-Asset-Value | 1.11 | |||||
| Price-to-Net-Cash | 1.64 | |||||
| Earnings Yield (Greenblatt) % | 51.28 | |||||
| FCF Yield % | 4.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
OrbusNeich Medical Group Holdings Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 141.094 | ||
| EPS (TTM) (€) | 0 | ||
| Beta | 0 | ||
| Volatility % | 63.79 | ||
| 14-Day RSI | 47.28 | ||
| 14-Day ATR (€) | 0.025618 | ||
| 20-Day SMA (€) | 0.3224 | ||
| 12-1 Month Momentum % | -55.64 | ||
| 52-Week Range (€) | 0.282 - 1.03 | ||
| Shares Outstanding (Mil) | 825.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OrbusNeich Medical Group Holdings Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
OrbusNeich Medical Group Holdings Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
OrbusNeich Medical Group Holdings Ltd Frequently Asked Questions
What is OrbusNeich Medical Group Holdings Ltd(FRA:Q8T)'s stock price today?
The current price of FRA:Q8T is €0.31. The 52 week high of FRA:Q8T is €1.03 and 52 week low is €0.28.
When is next earnings date of OrbusNeich Medical Group Holdings Ltd(FRA:Q8T)?
The next earnings date of OrbusNeich Medical Group Holdings Ltd(FRA:Q8T) is 2024-11-15 Est..
Does OrbusNeich Medical Group Holdings Ltd(FRA:Q8T) pay dividends? If so, how much?
The Dividend Yield %  of OrbusNeich Medical Group Holdings Ltd(FRA:Q8T) is 3.83% (As of Today), Highest Dividend Payout Ratio of OrbusNeich Medical Group Holdings Ltd(FRA:Q8T) was 0. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of OrbusNeich Medical Group Holdings Ltd(FRA:Q8T) is 3.83%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers